Skip to main content
Erschienen in: International Urology and Nephrology 4/2009

01.12.2009 | Nephrology - Original Paper

Impact of acute kidney injury on metformin-associated lactic acidosis

verfasst von: Yao-Ko Wen

Erschienen in: International Urology and Nephrology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Metformin has been shown to reduce diabetic complications in overweight patients, and is increasingly used to treat this condition. However, this agent is associated with a rare but serious risk of lactic acidosis.

Methods

From January 2004 to November 2008, 11 cases of metformin-associated lactic acidosis were seen at a medical center in Taiwan. The patients’ records were retrospectively reviewed with respect to clinical presentation, biochemical data, therapeutic strategies, and outcomes.

Results

Ten out of 11 patients with acute kidney injury were enrolled in this study. From their pre-existing states, these patients would have been considered at low risk of developing lactic acidosis. However, all of them had acute intercurrent conditions that might compromise renal function. Among them, six patients were ventilated and five patients had severe hypotension with vasoactive support. Nine patients received renal replacement therapy to clear the acidosis and treat the renal failure. All but one of our patients survived. Recovery of renal function was the general rule in survivors.

Conclusions

Metformin-associated lactic acidosis is commonly accompanied with acute kidney injury. In spite of the severity of their illness, the outcome is favorable with intensive support of the cardiovascular, respiratory, and renal systems.
Literatur
1.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef
2.
Zurück zum Zitat Stang M, Wysowski DK, Butler-Jones D (1999) Incidence of lactic acidosis in metformin user. Diabetes Care 22:925–927CrossRefPubMed Stang M, Wysowski DK, Butler-Jones D (1999) Incidence of lactic acidosis in metformin user. Diabetes Care 22:925–927CrossRefPubMed
3.
Zurück zum Zitat Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA (1998) Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338:265–266CrossRefPubMed Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA (1998) Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338:265–266CrossRefPubMed
4.
Zurück zum Zitat Brown JB, Pedula K, Barzilay J, Herson MK, Latare P (1998) Lactic acidosis rates in type 2 diabetes. Diabetes Care 21:1659–1663CrossRefPubMed Brown JB, Pedula K, Barzilay J, Herson MK, Latare P (1998) Lactic acidosis rates in type 2 diabetes. Diabetes Care 21:1659–1663CrossRefPubMed
5.
Zurück zum Zitat Misbin RI (2004) The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 27:1791–1793CrossRefPubMed Misbin RI (2004) The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 27:1791–1793CrossRefPubMed
6.
Zurück zum Zitat Salpeter S, Greyber E, Pasternak G, Salpeter E (2006) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 25:CD002967 Salpeter S, Greyber E, Pasternak G, Salpeter E (2006) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 25:CD002967
7.
Zurück zum Zitat Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute Dialysis Quality Initiative workgroup. Acute renal failure–definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204–R212CrossRefPubMed Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute Dialysis Quality Initiative workgroup. Acute renal failure–definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204–R212CrossRefPubMed
8.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed
10.
Zurück zum Zitat Canadian Pharmacists Association (2001) Compendium of pharmaceuticals and specialties. The Association, Ottawa Canadian Pharmacists Association (2001) Compendium of pharmaceuticals and specialties. The Association, Ottawa
11.
Zurück zum Zitat Herrington WG, Levy JB (2008) Metformin: effective and safe in renal disease? Int Urol Nephrol 40:411–417CrossRefPubMed Herrington WG, Levy JB (2008) Metformin: effective and safe in renal disease? Int Urol Nephrol 40:411–417CrossRefPubMed
12.
Zurück zum Zitat Chu CK, Chang YT, Lee BJ, Hu SY, Hu WH, Yang DY (2003) Metformin-associated lactic acidosis and acute renal failure in a type 2 diabetic patient. J Chin Med Assoc 66:505–508PubMed Chu CK, Chang YT, Lee BJ, Hu SY, Hu WH, Yang DY (2003) Metformin-associated lactic acidosis and acute renal failure in a type 2 diabetic patient. J Chin Med Assoc 66:505–508PubMed
13.
Zurück zum Zitat Almirall J, Bricullé M, Gonzalez-Clemente JM (2008) Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice. Nephrol Dial Transplant 23:2436–2438CrossRefPubMed Almirall J, Bricullé M, Gonzalez-Clemente JM (2008) Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice. Nephrol Dial Transplant 23:2436–2438CrossRefPubMed
14.
Zurück zum Zitat Gudmundsdottir H, Aksnes H, Heldal K, Krogh A, Froyshov S, Rudberg N, Os I (2006) Metformin and antihypertensive therapy with drugs blocking the renin angiotensin system, a cause of concern? Clin Nephrol 66:380–385PubMed Gudmundsdottir H, Aksnes H, Heldal K, Krogh A, Froyshov S, Rudberg N, Os I (2006) Metformin and antihypertensive therapy with drugs blocking the renin angiotensin system, a cause of concern? Clin Nephrol 66:380–385PubMed
15.
Zurück zum Zitat Audia P, Feinfeld DA, Dubrow A, Winchester JF (2008) Metformin-induced lactic acidosis and acute pancreatitis precipitated by diuretic, celecoxib, and candesartan-associated acute kidney dysfunction. Clin Toxicol (Phila) 46:164–166 Audia P, Feinfeld DA, Dubrow A, Winchester JF (2008) Metformin-induced lactic acidosis and acute pancreatitis precipitated by diuretic, celecoxib, and candesartan-associated acute kidney dysfunction. Clin Toxicol (Phila) 46:164–166
16.
Zurück zum Zitat Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA (2006) RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 10:R73CrossRefPubMed Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA (2006) RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 10:R73CrossRefPubMed
17.
Zurück zum Zitat Lalau JD, Andrejak M, Morinière P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J (1989) Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 27:285–288PubMed Lalau JD, Andrejak M, Morinière P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J (1989) Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 27:285–288PubMed
18.
Zurück zum Zitat Heaney D, Majid A, Junor B (1997) Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant 12:1046–1047CrossRefPubMed Heaney D, Majid A, Junor B (1997) Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant 12:1046–1047CrossRefPubMed
Metadaten
Titel
Impact of acute kidney injury on metformin-associated lactic acidosis
verfasst von
Yao-Ko Wen
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 4/2009
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-009-9549-6

Weitere Artikel der Ausgabe 4/2009

International Urology and Nephrology 4/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.